Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder.
| Publication Type | Academic Article |
| Authors | Mathew S, Price R, Mao X, Smith E, Coplan J, Charney D, Shungu D |
| Journal | Biol Psychiatry |
| Volume | 63 |
| Issue | 9 |
| Pagination | 891-8 |
| Date Published | 10/29/2007 |
| ISSN | 1873-2402 |
| Keywords | Anti-Anxiety Agents, Anxiety Disorders, Aspartic Acid, Excitatory Amino Acid Antagonists, Hippocampus, Magnetic Resonance Spectroscopy, Riluzole |
| Abstract | BACKGROUND: Previous research has suggested the therapeutic potential of glutamate-modulating agents for severe mood and anxiety disorders, potentially resulting from enhancement of neuroplasticity. We used proton magnetic resonance spectroscopic imaging ((1)H MRSI) to examine the acute and chronic effects of the glutamate-release inhibitor riluzole on hippocampal N-acetylaspartate (NAA), a neuronal marker, in patients with generalized anxiety disorder (GAD) and examined the relationship between changes in NAA and clinical outcome. METHODS: Fourteen medication-free GAD patients were administered open-label riluzole and then evaluated by (1)H MRSI before drug administration, and 24 hours and 8 weeks following treatment. Patients were identified as responders (n = 9) or nonresponders (n = 5). Seven untreated, medically healthy volunteers, comparable in age, sex, IQ, and body mass index to the patients, received scans at the same time intervals. Molar NAA concentrations in bilateral hippocampus, and change in anxiety ratings were the primary outcome measures. RESULTS: A group-by-time interaction was found, with riluzole responders showing mean increases in hippocampal NAA across the three time points, whereas nonresponders had decreases over time. In GAD patients at Week 8, hippocampal NAA concentration and proportional increase in NAA from baseline both were positively associated with improvements in worry and clinician-rated anxiety. CONCLUSIONS: These preliminary data support a specific association between hippocampal NAA and symptom alleviation following riluzole treatment in GAD. Placebo-controlled investigations that examine hippocampal NAA as a viable surrogate endpoint for clinical trials of neuroprotective and plasticity-enhancing agents are warranted. |
| DOI | 10.1016/j.biopsych.2007.09.012 |
| PubMed ID | 18028881 |
| PubMed Central ID | PMC2385784 |